SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZBX - Genzyme Biosurgery
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joan Osland Graffius who wrote (10)5/30/2001 10:46:21 AM
From: RRICH4   of 18
 
The yearly meeting of colorectal surgeons starts this weekend in San Diego and Genzyme BioSurgical (GZBX), a division of Genzyme General (GENZ), will present clinical data on its new product to prevent adhesions, also known as scar tissue, after major abdominal surgery. Post-surgical scar tissue is a major health problem, causing recurrent bowel obstructions that lead to repeated hospitalizations and more operations. It is a vicious cycle. Today, there is no good treatment for this major problem that greatly soaks up health care dollars. This new product is a synthetic material placed inside the abdominal cavity at the end of surgery to prevent scar tissue from forming at the incision site. I anticipate Genzyme BioSurgical's data to support the use of their product in preventing surgical adhesions. Given the enormity of the market and the fact that this product is unique and easy to use, expect the company to attract investor interest right up to the presentation on Monday. (from TradingMarkets.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News